CHEMBL4245414-Cpd2g
General
Type : Quinoline, Piperazine, Pyrrolidine, Organochlorine
Chemical_Nomenclature : 2-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]-1-pyrrolidin-1-ylethanone
Canonical SMILES : C1CCN(C1)C(=O)CN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl
InChI : InChI=1S\/C19H23ClN4O\/c20-15-3-4-16-17(13-15)21-6-5-18(16)23-11-9-22(10-12-23)14-19(25)24-7-1-2-8-24\/h3-6,13H,1-2,7-12,14H2
InChIKey : OBBLGGTVVLXSCX-UHFFFAOYSA-N
Other name(s) : 1-(2-(4-(7-Chloro-4-quinolyl)piperazin-1-yl)acetyl)pyrrolidine || Compound 2g || CHEMBL4245414 || BDBM152800 || AKOS034528164 || Z68339437
MW : 358.9
Formula : C19H23ClN4O
CAS_number :
PubChem : 91937923
UniChem : OBBLGGTVVLXSCX-UHFFFAOYSA-N
Target
Families : CHEMBL4245414-Cpd2g ligand of proteins in family
DPP4N_Peptidase_S9
Protein :
human-DPP4
References (1)
| Title : Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes - Kushwaha_2015_Chem.Biol.Drug.Des_85_439 |
| Author(s) : Kushwaha RN , Srivastava R , Mishra A , Rawat AK , Srivastava AK , Haq W , Katti SB |
| Ref : Chemical Biology Drug Des , 85 :439 , 2015 |
| Abstract : |
| PubMedSearch : Kushwaha_2015_Chem.Biol.Drug.Des_85_439 |
| PubMedID: 25216392 |